Advances in End-Stage Renal Diseases 2001
International Conference on Dialysis III, January 18–19, 2001, Miami Beach, Fla.
Editors: Nathan W. Levin, New York, N.Y.; Claudio Ronco, Vicenza

Paper

First Clinical Experience with an Adjunctive Hemoperfusion Device Designed Specifically to Remove β₂-Microglobulin in Hemodialysis
Claudio Ronco^a,b, Alessandra Brendolan^b, James F. Winchester^d, Ellen Golds^d, Jonathan Clemmer^d, Hans Dietrich Polaschegg^c, Thomas E. Muller^d, Giuseppe La Greca^b, Nathan W. Levin<sup>a

a</sup>Renal Research Institute, New York, N.Y., USA;
^bOspedale San Bortolo, Vicenza, Italy;
^cKoestenberg, Austria;
^dRenalTech International, New York, N.Y., USA

Address of Corresponding Author

Blood Purif 2001;19:260-263 (DOI: 10.1159/000046952)

  Abstract

Sorry, there is no abstract. Read the first few lines of the text instead!

β₂-Microglobulin, a middle molecular weight protein (11.8 kD), has increasingly been the focus of attention in its role as the precursor of dialysis-related amyloidosis (DRA) [1]. Current evidence favors the alteration of β₂-microglobulin by glycosylation [2], and subsequent deposition of glycosylated β₂-microglobulin as amyloid fibrils in many tissues, particularly in large joints (shoulders), and in the carpal tunnel. DRA in chronic dialysis patients can produce bone cysts, severe carpal tunnel syndrome and crippling arthritis [3]. While there is poor correlation between blood concentrations of β₂-microglobulin and DRA, there is direct correlation of this complication with duration of dialysis. Moreover, the disposition of β₂-microglobulin, follows a 3-pool kinetic model with distribution in plasma water, extracellular fluid and a slow equilibration compartment [4].

Copyright © 2001 S. Karger AG, Basel

  Author Contacts

Claudio Ronco, MD
Department of Nephrology
St. Bortolo Hospital
I–36100 Vicenza (Italy)
E-Mail cronco@goldnet.it

  Article Information

Number of Print Pages : 4
Number of Figures : 5, Number of Tables : 0, Number of References : 14